ADRX, INC.

Westlake Village, CA · Biotech · Private

Monoclonal antibody targeting transthyretin monomeric intermediates to prevent amyloid aggregation in ATTR disease

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Westlake Village, CA
Latest Form D: $6M, Dec 2020
Total capital: $19.1M

Federal grants: $1M; 3 awards · 2022; Rank in peer group#298 of 326
Private capital raised: $18.1M; 4 Form D · last Dec 2020; 71 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 10 pending · first 2021; Rank in peer group#58 of 326

Capital timeline

Latest events

Sep 2022Federal grantHealth and Human S · Phase I · Brain-penetrant chemical disaggregators of tau fibrils as therapeutics for Alzheimer's Disease$477K
Aug 2022Federal grantHealth and Human S · Phase I · Development of a Blood-based Diagnostic for Early Detection of Transthyretin Amyloidosis$270K
Jun 2022Federal grantHealth and Human S · Phase I · Therapeutic Immunodepletion of a Transthyretin Aggregation Intermediate$256K
Dec 2020Private capital raisedForm D · SEC · 4th filing$6M
Oct 2020Private capital raisedForm D · SEC · 3rd filing$5.6M
Oct 2020Private capital raisedForm D · SEC · 2nd filing$4M
Oct 2020Private capital raisedForm D · SEC · 1st filing$2.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#58 · top 18%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Marcin ApostolResearcherExecutive OfficerLinked by $1M in grants as PI
David WilcoxExecutive OfficerNamed in SEC Form D filings
Doug LaneExecutive OfficerNamed in SEC Form D filings
Gary WilcoxDirectorNamed in SEC Form D filings
James TreanorDirectorNamed in SEC Form D filings
John FrankDirectorNamed in SEC Form D filings

Show all 8 people

Madhavan BalachandranExecutive Officer, DirectorNamed in SEC Form D filings
Reza HalseDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 12

Jan 16, 2025PendingTransthyretin (ttr) Monomer Binding AntibodiesUSPTOApplication 18708912
May 4, 2023PendingTau Aggregation InhibitorsUSPTOApplication 16615026
Sep 27, 2022GrantedTau Aggregation Peptide InhibitorsUSPTOUS 11,453,701

Show all 12 patent records

Transthyretin (ttr) Monomer Binding AntibodiesJan 16, 2025 · Application 18708912Pending
Tau Aggregation InhibitorsMay 4, 2023 · Application 16615026Pending
Tau Aggregation Peptide InhibitorsSep 27, 2022 · US 11,453,701Granted
Peptide Inhibitors Of Transcription Factor AggregationSep 14, 2021 · US 11,117,930Granted
Peptide Inhibitors Of Transcription Factor AggregationApplication PCTUS2018019417Pending
Tau Peptide InhibitorsApplication 62547586Pending
Tau Aggregation InhibitorsApplication 62516393Pending
Transthyretin (ttr) Monomer Binding AntibodiesApplication 63278925Pending
Peptide Inhibitors Of Transcription FactorsApplication 62462815Pending
Transthyretin (ttr) Monomer Binding AntibodiesApplication PCTUS2022079810Pending
Tau Peptide InhibitorsApplication PCTUS2018047108Pending
Tau Aggregation InhibitorsApplication PCTUS2018036507Pending

Peel Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
Rgenta Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
REVEL PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
TRANSCODE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
1910 GENETICS INC.Similar federal contract value in Biotech · null in contracts
ELYSIUM THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.